GEP20063860B - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates

Info

Publication number
GEP20063860B
GEP20063860B GE5599A GEAP2002005599A GEP20063860B GE P20063860 B GEP20063860 B GE P20063860B GE 5599 A GE5599 A GE 5599A GE AP2002005599 A GEAP2002005599 A GE AP2002005599A GE P20063860 B GEP20063860 B GE P20063860B
Authority
GE
Georgia
Prior art keywords
growth hormone
human growth
chemically
modified human
conjugate
Prior art date
Application number
GE5599A
Other languages
English (en)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of GEP20063860B publication Critical patent/GEP20063860B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GE5599A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates GEP20063860B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
GEP20063860B true GEP20063860B (en) 2006-06-26

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5599A GEP20063860B (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (ja)
JP (2) JP2005525302A (ja)
KR (2) KR20070072924A (ja)
CN (1) CN1608079A (ja)
AP (1) AP2004003050A0 (ja)
AU (1) AU2002356990A1 (ja)
BR (1) BR0214451A (ja)
CA (1) CA2467731A1 (ja)
CO (1) CO5580794A2 (ja)
EA (2) EA200700431A1 (ja)
EC (1) ECSP045114A (ja)
GE (1) GEP20063860B (ja)
HR (1) HRP20040448A2 (ja)
HU (1) HUP0500997A2 (ja)
IL (1) IL162031A0 (ja)
IS (1) IS7268A (ja)
MA (1) MA27544A1 (ja)
MX (1) MXPA04004809A (ja)
NO (1) NO20042182L (ja)
OA (1) OA13063A (ja)
PL (1) PL374354A1 (ja)
RS (1) RS53104A (ja)
TN (1) TNSN04090A1 (ja)
WO (1) WO2003044056A2 (ja)
ZA (1) ZA200403907B (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003061577A2 (en) * 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
JP4764630B2 (ja) 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035553A2 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
US8080391B2 (en) * 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
US8034326B2 (en) 2005-04-18 2011-10-11 Novo Nordisk A/S IL-21 variants
RU2008105545A (ru) * 2005-08-30 2009-10-10 Ново Нордиск Хелс Кеа Аг (Ch) Жидкие препараты пэгилированного гормона роста
DE602006020480D1 (de) * 2005-11-08 2011-04-14 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP2040757A2 (en) * 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
BRPI0822530B1 (pt) * 2008-04-03 2022-03-22 Biosteed Gene Expression Tech. Co., Ltd Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽-聚合物綴合物
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
MX2012013375A (es) * 2010-05-17 2013-04-11 Cebix Inc Peptido c pegilado.
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
EA037151B1 (ru) 2014-11-06 2021-02-11 Фармаэссентия Корпорейшн Способ лечения с использованием пегилированного интерферона
EP3220892B1 (en) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016145388A1 (en) * 2015-03-11 2016-09-15 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer
CN108026182B (zh) 2015-09-18 2022-04-26 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK1568772T3 (da) * 1995-09-21 2010-10-18 Genentech Inc Varianter af humant væksthormon
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
PL374354A1 (en) 2005-10-17
HUP0500997A2 (en) 2007-11-28
MA27544A1 (fr) 2005-10-03
KR20050044858A (ko) 2005-05-13
AU2002356990A1 (en) 2003-06-10
WO2003044056A3 (en) 2003-08-21
CN1608079A (zh) 2005-04-20
AP2004003050A0 (en) 2004-06-30
OA13063A (en) 2006-11-10
EA200700431A1 (ru) 2008-02-28
MXPA04004809A (es) 2004-08-11
NO20042182L (no) 2004-08-11
CA2467731A1 (en) 2003-05-30
JP2006321808A (ja) 2006-11-30
HRP20040448A2 (en) 2006-02-28
WO2003044056A2 (en) 2003-05-30
EA200400565A1 (ru) 2005-06-30
JP2005525302A (ja) 2005-08-25
EA008505B1 (ru) 2007-06-29
TNSN04090A1 (fr) 2006-06-01
ZA200403907B (en) 2007-12-27
IL162031A0 (en) 2005-11-20
RS53104A (en) 2006-10-27
IS7268A (is) 2004-05-17
BR0214451A (pt) 2006-05-30
CO5580794A2 (es) 2005-11-30
EP1453859A2 (en) 2004-09-08
KR20070072924A (ko) 2007-07-06
ECSP045114A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
GEP20063860B (en) Chemically-modified human growth hormone conjugates
JPH02504279A (ja) インスリン様成長因子1(igf‐1)または因子2(igf‐2)の類縁ペプチド
EA200000601A1 (ru) Сайт - специфичное получение конъюгатов grf с полиэтиленгликолем
RS63504A (en) Polyalkylene polymer compounds and uses thereof
HUT75533A (en) Improved interferon polymer conjugates
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
CA2345027A1 (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
MXPA02006215A (es) Metodo para preparar esteres de 1-benzotriazolil carbonato de poli(etilenglicol).
AR044024A1 (es) Mutante de sustitucion de la il-18 humana, composicion biologicamente activa que la comprende, su uso para preparar dicha composicion, metodo para prepararla y metodo para mejorar la farmacocinetica y farmacodinamica de dicha il-18 humana
AU2005232475A1 (en) Novel g-csf conjugates
GB2355009A (en) Peptides conjugated to bile acids/salts
EP1763535B1 (de) Mit einem organischem rest verbundenes polypeptid
IL131381A0 (en) Therapeutic agent for lymphatic tumors
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
CA2444266A1 (en) Use of bile acid or bile salt fatty acid conjugates
AR042103A1 (es) Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
KR890700606A (ko) 생물학적 활성분자
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
KR960000921A (ko) 칼시토닌 유도체 및 그 용도
CA2498062A1 (en) Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol)
PT918795E (pt) Droga antiangiogenica para tratar cancro artrite e retinopatia